fbpx Skip to main content

In preparation for presenting at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition, biotechnology company Amgen recently shared a preview of the data of a follow-up to a phase 3 trial focused on pediatric patients and the initial safety and efficacy results of the addition of KYPROLIS to the treatment for patients with relapsed/refractory acute lymphoblastic leukemia (ALL). Amgen has over 15 sponsored clinical studies and abstracts this year that will be included in the meeting.

Amgen highlighted its study and results of an updated phase 3 trial of over 200 children with high-risk first relapse B-cell precursor acute lymphoblastic leukemia (B-ALL). Data indicated that when including BLINCYTO® (blinatumomab) as part of Amgen’s bispecific T-cell engager (BiTE®) platform, there was an improvement to patients’ event-free survival and overall survival when compared to allogeneic hematopoietic stem cell transplant (alloHSCT).

Also noted in Amgen’s press release prior to ASH was the promising results of a study examining the combination of KYPROLIS with vincristine, dexamethasone, PEG-asparaginase, daunorubicin (VXLD) induction therapy in children with relapsed/refractory ALL. Using this combination of treatment, they found efficacy in pediatric patients experiencing highly advanced forms of the disease.

Amgen is also connected to an oral presentation during ASH about exposure to Nplate during pregnancy and the outcomes of the fetuses and infants. They shared in their preview that there were no safety concerns identified from the analyses of the Pregnancy Surveillance Program (PSP).

Dr. David M. Reese, Executive Vice President of Research and Development for Amgen, reiterated the company’s “commitment to reaching more patients with [their] innovative hematology medicines and improving the patient experience by exploring more convenient administrations for people living with blood cancers [1].”

You May Also Like::  CAR-T Therapy Shows Promise for Multiple Myeloma but With Barriers


[1] Amgen. (2021, December 7). Amgen announces new data being presented at ASH 2021[Press release]. https://www.obroncology.com/news/amgen-announces-new-data-being-presented-at-ash-2021